Brief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program

Bristol-Myers Squibb Co

27/01/2026 21:44

Jan 27 (Reuters) - Centers for Medicare & Medicaid Services (CMS):

CMS ANNOUNCES SELECTION OF DRUGS FOR THE THIRD CYCLE OF THE MEDICARE DRUG PRICE NEGOTIATION PROGRAM

CMS: DRUGS SELECTED FOR THIRD CYCLE OF MEDICARE DRUG PRICE NEGOTIATION ARE REXULTI, TRULICITY, VERZENIO, XELJANZ; XELJANZ XR AND XOLAIR

CMS: DRUGS SELECTED FOR THIRD CYCLE OF MEDICARE DRUG PRICE NEGOTIATION ARE ENTYVIO, ERLEADA, KISQALI ,LENVIMA, ORENCIA

CMS: SELECTED DRUGS FOR THIRD CYCLE OF MEDICARE DRUG PRICE NEGOTIATIONS ARE ANORO ELLIPTA, BIKTARVY, BOTOX; BOTOX COSMETIC, CIMZIA, COSENTYX

CMS: DRUG TRADJENTA CHOSEN FOR RENEGOTIATION FOR THE THIRD CYCLE OF THE MEDICARE DRUG PRICE NEGOTIATION PROGRAM

CMS-ANY NEGOTIATED & RENEGOTIATED DRUG PRICES OF SELECTED DRUGS FOR THIRD CYCLE OF MEDICARE DRUG PRICE NEGOTIATION PROGRAM TO BECOME EFFECTIVE IN 2028

Further company coverage: LLY.N

 ((Reuters.Briefs@thomsonreuters.com;))